Stockscreener 앱 받기
7.45
18.82%
1.18
시간 외 거래:
7.47
0.02
+0.27%
전일 마감가:
$6.27
열려 있는:
$6.5
하루 거래량:
51,484
Relative Volume:
2.46
시가총액:
$142.38M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+11.86%
1개월 성능:
-7.45%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$6.47
$7.80
1주일 범위
$5.51
$7.80
52주 변동 폭
$5.51
$10.16
Actuate Therapeutics Inc Stock (ACTU) Company Profile
명칭
Actuate Therapeutics Inc
전화
847-986-4190
주소
1751 RIVER RUN, FORT WORTH
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail
Actuate Announces Scientific Reports Publication on - GlobeNewswire
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor - Yahoo Finance
Achilles Therapeutics Announces Strategic Update - StockTitan
Cintas (NASDAQ:CTAS) PT Raised to $225.00 - Defense World
Cintas (NASDAQ:CTAS) PT Raised to $225.00 at Truist Financial - MarketBeat
Capricor rises as it expands deal with Nippon Shinyaku - The Pharma Letter
Capricor Therapeutics Secures Lucrative European Partnership - TipRanks
Capricor Therapeutics Signs Binding Term Sheet with Nippon - GlobeNewswire
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - StockTitan
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga
Actuate Announces Upcoming Presentation on Initial Data on - GlobeNewswire
Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR
Behind the Bell: Actuate Therapeutics - Nasdaq
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas - GlobeNewswire
Actuate gains FDA orphan drug status for cancer treatment - Investing.com
Biopharma financings near $78B, almost double last year’s value - BioWorld Online
Elraglusib shows promise in Ewing sarcoma trial - Investing.com
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - GlobeNewswire
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - GlobeNewswire Inc.
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Actuate Therapeutics (NASDAQ:ACTU) Stock Quotes, Forecast and News Summary - Benzinga
Actuate Therapeutics’ $22,4 Million Initial Public Offering - Global Legal Chronicle
Actuate Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Actuate Therapeutics Rings the Opening Bell - Nasdaq
Wheeling Native Daniel Schmitt To Ring Wall Street Bell - Wheeling Intelligencer
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 - GlobeNewswire
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 - StockTitan
Actuate Therapeutics appoints new accounting firm By Investing.com - Investing.com Australia
Actuate Therapeutics appoints new accounting firm - Investing.com India
Actuate Therapeutics appoints new accounting firm - Investing.com
Actuate Therapeutics appoints new accounting firm By Investing.com - Investing.com UK
IPO Roundup: WeRide, Reitar Logtech and more (NYSEARCA:IPO) - Seeking Alpha
Todd S. Thomson Sells 18,750 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock - Defense World
Opening Day: Actuate Therapeutics makes public debut - TipRanks
Actuate therapeutics insider sells $150,000 worth of shares By Investing.com - Investing.com Australia
Actuate therapeutics insider sells $150,000 worth of shares By Investing.com - Investing.com Canada
Actuate therapeutics insider sells $150,000 worth of shares - Investing.com
Items Tagged with 'glycogen synthase kinase-3 inhibitor' - BioWorld Online
Biopharma IPO volume at 10-year low; Actuate raises $22.4M - BioWorld Online
Leslie W. Kreis Sells 24,999 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Director Equity Cof Lp Bios Purchases 500,000 Shares - Defense World
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com UK
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com Australia
Actuate Therapeutics insiders buy $4m in stock, sell $234k By Investing.com - Investing.com South Africa
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com Canada
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com
Actuate Therapeutics insiders buy $4m in stock, sell $234k - Investing.com India
Actuate Therapeutics insiders execute stock transactions worth over $4m By Investing.com - Investing.com South Africa
Actuate Therapeutics insiders execute stock transactions worth over $4m By Investing.com - Investing.com Australia
Actuate Therapeutics Inc (ACTU) 재무 분석
Actuate Therapeutics Inc (ACTU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):